sarpogrelate has been researched along with Cardiac Edema in 1 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarpogrelate (4 mg/kg) was infused intravenously for 30 min either before LCA occlusion or at reperfusion." | 1.33 | 5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. ( Maeda, H; Murio, Y; Rajesh, KG; Sasaguri, S; Suzuki, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajesh, KG | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Murio, Y | 1 |
| Sasaguri, S | 1 |
1 other study available for sarpogrelate and Cardiac Edema
| Article | Year |
|---|---|
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Caspase 3; Caspases; Down-Regulation; Edema, Cardiac; Heart; | 2006 |